These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 1823318)

  • 1. Neutralization of divergent HIV-1 isolates by conformation dependent human antibodies to gp120.
    Dis Markers; 1991; 9(6):344-5. PubMed ID: 1823318
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Kwong PD; Doyle ML; Casper DJ; Cicala C; Leavitt SA; Majeed S; Steenbeke TD; Venturi M; Chaiken I; Fung M; Katinger H; Parren PW; Robinson J; Van Ryk D; Wang L; Burton DR; Freire E; Wyatt R; Sodroski J; Hendrickson WA; Arthos J
    Nature; 2002 Dec; 420(6916):678-82. PubMed ID: 12478295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virology. HIV may shed some protection as it jumps to new hosts.
    Cohen J
    Science; 2004 Mar; 303(5666):1956. PubMed ID: 15044774
    [No Abstract]   [Full Text] [Related]  

  • 8. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
    Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F; Theze J; Zouali M
    Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
    Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human antibodies to HIV-1 by recombinant DNA methods.
    Burton DR; Barbas CF
    Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant gp120 specifically enhances tumour necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors.
    Dis Markers; 1991; 9(6):342-4. PubMed ID: 1823317
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.
    Buchbinder A; Karwowska S; Gorny MK; Burda ST; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):425-7. PubMed ID: 1599752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.